Adma Biologics (ADMA) Intangibles (2017 - 2026)
Adma Biologics' (ADMA) quarterly Intangibles came in at $632000.0 in Q4 2025, up 37.39% YoY from $460000.0 in Q4 2024, and up 28.72% on a QoQ basis from $491000.0 in Q3 2025.
Adma Biologics (ADMA) Intangibles (2017 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 9 years of Intangibles data on file, last reported at $632000.0 in Q4 2025.
- Quarterly Intangibles rose 37.39% year-over-year to $632000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $632000.0 (up 37.39% YoY) and the FY2025 annual result came in at $632000.0, up 37.39% from the prior year.
- Intangibles advanced to $632000.0 in Q4 2025, from $491000.0 in the prior quarter.
- In the past five years, Intangibles ranged from a high of $6.1 million in Q1 2021 to a low of $321000.0 in Q1 2024.
- A 5-year average of $2.0 million and a median of $745158.5 in 2023 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2023 — Intangibles tumbled 90.48% — and 2024, when it surged 743.63%.
- Tracing ADMA's Intangibles over 5 years: stood at $1.7 million in 2021, then sank by 41.4% to $1.0 million in 2022, then plunged by 50.74% to $499000.0 in 2023, then slipped by 7.82% to $460000.0 in 2024, then jumped by 37.39% to $632000.0 in 2025.
- The last three Intangibles figures came in at $632000.0 (Q4 2025), $491000.0 (Q3 2025), and $527000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 575,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 575,000.00 |
| Dec 31, 2025 | 632,000.00 |
| Sep 30, 2025 | 491,000.00 |
| Jun 30, 2025 | 527,000.00 |
| Mar 31, 2025 | 452,000.00 |
| Dec 31, 2024 | 460,000.00 |
| Sep 30, 2024 | 485,000.00 |
| Jun 30, 2024 | 5.53 Mn |
| Mar 31, 2024 | 321,000.00 |
| Dec 31, 2023 | 499,000.00 |
| Sep 30, 2023 | 476,902.00 |
| Jun 30, 2023 | 655,740.00 |
| Mar 31, 2023 | 834,577.00 |
| Dec 31, 2022 | 1.01 Mn |
| Sep 30, 2022 | 5.01 Mn |
| Jun 30, 2022 | 1.37 Mn |
| Mar 31, 2022 | 5.01 Mn |
| Dec 31, 2021 | 1.73 Mn |
| Sep 30, 2021 | 6.08 Mn |
| Jun 30, 2021 | 2.09 Mn |